PMID- 30466805
DCOM- 20190221
LR  - 20190221
IS  - 1095-6859 (Electronic)
IS  - 0090-8258 (Linking)
VI  - 152
IP  - 2
DP  - 2019 Feb
TI  - Early tumor regrowth is a contributor to impaired survival in patients with
      completely resected advanced ovarian cancer. An exploratory analysis of the
      Intergroup trial AGO-OVAR 12.
PG  - 235-242
LID - S0090-8258(18)31406-9 [pii]
LID - 10.1016/j.ygyno.2018.11.008 [doi]
AB  - OBJECTIVE: Surgical assessment of residual tumor provides the strongest
      prognostic information in advanced ovarian cancer (AOC), with the best outcome
      observed after complete resection. Postoperative radiological assessment before
      initiation of chemotherapy can supplement the information obtained by surgical
      assessment; however, it may also reveal conflicting findings. METHODS: Patients
      with AOC enrolled in the AGO-OVAR 12 trial underwent baseline imaging before the 
      first chemotherapy cycle. The findings from surgical and radiologic assessment
      for disease extend were compared. Additionally, an integrated approach was
      assessed. RESULTS: Complete data from all 3 assessment methods were available for
      1345 patients. Of 689 patients with complete resection, tumor was observed in 28%
      and 22% of patients undergoing radiologic and integrated assessment,
      respectively. Patients with surgical- radiological and surgical-integrated
      concordant findings showed a 5-year overall survival (5Y-OS) of 72% and 71%,
      whereas patients with surgical-radiological and surgical-integrated discordant
      results showed inferior 5Y-OS of 47% and 49%, respectively. Patients with
      surgically assessed residual disease had a 5-YOS of 37%. The interval between
      surgery and baseline assessment was independently associated with discordance
      between assessment methods, which might reflect early tumor regrowth.
      CONCLUSIONS: Baseline tumor assessment before chemotherapy provides information
      that stratifies patients with complete resection into different prognostic
      groups. Integrating the data from different assessment methods might lead to
      improved definitions of prognostic groups. Further investigation to determine if 
      earlier initiation of chemotherapy after debulking surgery could increase
      survival of patients with early tumor regrowth is warranted.
CI  - Copyright (c) 2018. Published by Elsevier Inc.
FAU - Heitz, F
AU  - Heitz F
AD  - Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte,
      Evangelische Huyssens-Stiftung, Germany; Department for Gynecology, Charite -
      Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin,
      Humboldt-Universitat zu Berlin, and Berlin Institute of Health. Electronic
FAU - Harter, P
AU  - Harter P
AD  - Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte,
      Evangelische Huyssens-Stiftung, Germany.
FAU - Avall-Lundqvist, E
AU  - Avall-Lundqvist E
AD  - Linkoping University and Karolinska Institute, Linkoping, Sweden.
FAU - Reuss, A
AU  - Reuss A
AD  - Coordinating Center for Clinical Trials, Marburg, Germany.
FAU - Pautier, P
AU  - Pautier P
AD  - Institut Gustave Roussy, Villejuif, France.
FAU - Cormio, G
AU  - Cormio G
AD  - University of Bari and Gynecologic Oncology Unit, National Cancer Institute
      "Giovanni Paolo II", Bari, Italy.
FAU - Colombo, N
AU  - Colombo N
AD  - University of Milano-Bicocca and Instituto Europeo di Oncologia, Milan, Italy.
FAU - Reinthaller, A
AU  - Reinthaller A
AD  - Department of General Gynecology and Gynecologic Oncology, Gynecologic Cancer
      Unit - Comprehensive Cancer Center, Medical University of Vienna, Austria.
FAU - Vergote, I
AU  - Vergote I
AD  - University of Leuven, Leuven Cancer Institute, Leuven, Belgium.
FAU - Poveda, A
AU  - Poveda A
AD  - Instituto Valenciano de Oncologia, Valencia, Spain.
FAU - Ottevanger, P B
AU  - Ottevanger PB
AD  - Radboud University Medical Center, Nijmegen, Netherlands.
FAU - Hanker, L C
AU  - Hanker LC
AD  - University of Schleswig-Holstein, Lubeck, Germany.
FAU - Leminen, A
AU  - Leminen A
AD  - Women's Hospital, Haartmaninkatu 2, Helsinki, Finland.
FAU - Alexandre, J
AU  - Alexandre J
AD  - Hopitaux Universitaires Paris Centre, Hopital Cochin, Services de Cancerologie et
      d'Oncologie Gynecologique, 27, rue du Faubourg-Saint-Jacques, 75014 Paris,
FAU - Canzler, U
AU  - Canzler U
AD  - Department of Gynecology and Obstetrics, TU Dresden, Dresden, Germany.
FAU - Sehouli, J
AU  - Sehouli J
AD  - Charite Campus Virchow-Klinikum, Berlin, Germany.
FAU - Herrstedt, J
AU  - Herrstedt J
AD  - Odense University Hospital, Odense and Zealand University Hospital Roskilde,
FAU - Fiane, B
AU  - Fiane B
AD  - Department of Gynecology and Gynecologic Oncology, Stavanger University Hospital,
      Stavanger, Norway.
FAU - Merger, M
AU  - Merger M
AD  - Clinical Research, Boehringer Ingelheim Pharma, Biberach An der Riss, Germany.
FAU - du Bois, A
AU  - du Bois A
AD  - Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte,
      Evangelische Huyssens-Stiftung, Germany.
LA  - eng
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20181120
PL  - United States
TA  - Gynecol Oncol
JT  - Gynecologic oncology
JID - 0365304
RN  - 0 (Indoles)
RN  - BG3F62OND5 (Carboplatin)
RN  - G6HRD2P839 (nintedanib)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Carboplatin/administration & dosage
MH  - Carcinoma, Ovarian Epithelial/drug therapy/mortality/*pathology/*surgery
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Indoles/administration & dosage
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Neoplasm, Residual/pathology
MH  - Paclitaxel/administration & dosage
MH  - Prognosis
MH  - Young Adult
OT  - *Advanced ovarian cancer
OT  - *Debulking surgery
OT  - *Pre-chemotherapy imaging
OT  - *Prognosis
EDAT- 2018/11/24 06:00
MHDA- 2019/02/23 06:00
CRDT- 2018/11/24 06:00
PHST- 2018/09/24 00:00 [received]
PHST- 2018/10/30 00:00 [revised]
PHST- 2018/11/06 00:00 [accepted]
PHST- 2018/11/24 06:00 [pubmed]
PHST- 2019/02/23 06:00 [medline]
PHST- 2018/11/24 06:00 [entrez]
AID - S0090-8258(18)31406-9 [pii]
AID - 10.1016/j.ygyno.2018.11.008 [doi]
PST - ppublish
SO  - Gynecol Oncol. 2019 Feb;152(2):235-242. doi: 10.1016/j.ygyno.2018.11.008. Epub
      2018 Nov 20.